J. Torres, S. Mehandru, J. Colombel, and L. Peyrin-biroulet, Crohn's disease, Lancet, vol.389, pp.1741-1755, 2017.

R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-biroulet, J. Colombel et al., Lancet, vol.389, pp.1756-1770, 2017.

S. C. Ng, H. Y. Shi, N. Hamidi, F. E. Underwood, W. Tang et al., Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies, Lancet, vol.390, pp.2769-2778, 2018.

F. Magro, P. Gionchetti, R. Eliakim, S. Ardizzone, A. Armuzzi et al., Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders, J. Crohns Colitis, vol.11, pp.649-670, 2017.

L. Pouillon, M. Ferrante, G. Van-assche, P. Rutgeerts, M. Noman et al., Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab, Clin. Gastroenterol. Hepatol, vol.16, pp.1276-1283, 2018.

J. Colombel, R. Panaccione, P. Bossuyt, M. Lukas, F. Baert et al., Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, vol.390, pp.2779-2789, 2018.

M. E. Van-der-valk, M. J. Mangen, M. Leenders, G. Dijkstra, A. A. Van-bodegraven et al., Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF? therapy: Results from the COIN study, Gut, vol.63, pp.72-79, 2012.

J. Burisch, H. Vardi, N. Pedersen, M. Brinar, S. Cukovic-cavka et al., Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort, Inflamm. Bowel Dis, vol.21, pp.121-131, 2015.

R. K. Cross, G. Jambaulikar, P. Langenberg, J. K. Tracy, J. F. Collins et al., TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial, Contemp. Clin. Trials, vol.42, pp.132-144, 2015.

A. Zand, B. J. Kim, W. K. Van-deen, Z. Stokes, A. Platt et al., The effects of inflammatory bowel disease on caregivers: Significant burden and loss of productivity, BMC Health Serv. Res, vol.20, 2020.

P. Bossuyt, L. Pouillon, G. Bonnaud, S. Danese, and L. Peyrin-biroulet, E-health in inflammatory bowel diseases: More challenges than opportunities? Dig. Liver Dis, vol.49, pp.1320-1326, 2017.

R. K. Cross, P. Langenberg, M. Regueiro, D. A. Schwartz, J. K. Tracy et al., A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD), Am. J. Gastroenterol, vol.114, pp.472-482, 2019.

F. D'amico, S. Nancey, S. Danese, and L. Peyrin-biroulet, A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities, J. Crohns Colitis, 2020.

C. Maréchal, I. Aimone-gastin, C. Baumann, B. Dirrenberger, J. Guéant et al., Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United Eur, Gastroenterol. J, vol.5, pp.702-707, 2017.

A. Puolanne, K. Kolho, H. Alfthan, and M. Farkkila, Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study, Scand. J. Gastroenterol, vol.54, pp.849-854, 2019.

L. A. George, M. R. Dominic, and R. K. Cross, Integration of telemedicine into clinical practice for inflammatory bowel disease, Curr. Opin. Gastroenterol, vol.2020, pp.304-309

M. Elkjaer, M. Shuhaibar, J. Burisch, Y. Bailey, H. Scherfig et al., E-health empowers patients with ulcerative colitis: A randomised controlled trial of the web-guided 'Constant-care' approach, Gut, vol.59, pp.1652-1661, 2010.

D. Hoyo, J. Nos, P. Faubel, R. Muñoz, D. Domínguez et al., A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial, J. Med Internet Res, 2018.

D. Jong, M. J. Van-der-meulen-de-jong, A. E. Romberg-camps, M. J. Becx, M. C. Maljaars et al., Telemedicine for management of inflammatory bowel disease (myIBDcoach): A pragmatic, multicentre, randomised controlled trial, Lancet, vol.390, pp.959-968, 2017.

D. Jong, M. J. Boonen, A. Van-der-meulen-de-jong, A. E. Romberg-camps, M. J. Van-bodegraven et al., Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial, Clin. Gastroenterol. Hepatol, vol.18, pp.1744-1752, 2020.

, IBDoc®Calprotectin Home Test Kit Procedure

, Step Instructions for the QuantOn Cal®App|QuantOn Cal®, p.28, 2020.

C. Testkit, , p.28, 2020.

, Calprotectin Home Test for Patient Self Testing of Their IBD Status; Calprotectin, p.28, 2020.

Q. Cal, , p.28, 2020.

S. Haisma, A. Galaurchi, S. Almahwzi, J. A. Adekanmi-balogun, A. C. Muller-kobold et al., Head-to-head comparison of three stool calprotectin tests for home use, PLoS ONE, vol.14, 2019.

A. Mccombie, R. Walmsley, M. Barclay, C. Ho, T. Langlotz et al., A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients, Inflamm. Bowel Dis, vol.26, pp.1098-1109, 2019.

C. Bello, A. Roseth, J. Guardiola, C. Reenaers, A. Ruiz-cerulla et al., Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients, vol.49, pp.991-996, 2017.

S. Wei, C. Tung, M. Weng, and J. Wong, Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring, Intest. Res, vol.16, pp.546-553, 2018.

J. Hejl, K. Theede, B. Møllgren, K. V. Madsen, A. Heidari et al., Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis, Pract. Lab. Med, vol.10, pp.10-14, 2017.

K. K. Vinding, H. Elsberg, T. Thorkilgaard, E. Bélard, N. Pedersen et al., Fecal Calprotectin Measured By Patients at Home Using Smartphones-A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease, Inflamm. Bowel Dis, vol.22, pp.336-344, 2016.

D. V. Ankersen, P. Weimers, D. Marker, M. Bennedsen, S. Saboori et al., Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial, World J. Gastroenterol, vol.25, pp.6158-6171, 2019.

J. Weber, M. E. Ueberschlag, M. Prica, S. Kräuchi, C. Reinhard et al., Validation of a smartphone-based patient monitoring system measuring calprotectin as the therapy follow-up marker, J. Crohns Colitis, vol.1, pp.212-213, 2015.

A. Ibdoc®, , p.23, 2020.

C. Maaser, A. Sturm, S. R. Vavricka, T. Kucharzik, G. Fiorino et al., ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications, J. Crohns Colitis, vol.13, pp.144-164, 2018.

A. Buisson, F. Gonzalez, F. Poullenot, E. Sollellis, M. Flamant et al., Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools, Inflamm. Bowel Dis, vol.23, pp.1425-1433, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01595713

A. Heida, M. Knol, A. C. Kobold, J. Bootsman, G. Dijkstra et al., Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clin. Gastroenterol. Hepatol, vol.15, pp.1742-1749, 2017.

C. Disease, COVID-19) Situation Reports, p.29, 2020.

C. W. Lees, M. Regueiro, and U. Mahadevan, International Organization for the Study of Inflammatory Bowel Disease Innovation in IBD Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease, Gastroenterology, 2020.

S. Danese, B. E. Sands, S. C. Ng, and L. Peyrinbiroulet, The day after COVID-19 in IBD: How to go back to 'normal', Nat. Rev. Gastroenterol. Hepatol, 2020.

L. Zhou, J. Bao, I. M. Setiawan, A. Saptono, B. Parmanto et al., The mHealth App Usability Questionnaire (MAUQ): Development and Validation Study, JMIR mHealth uHealth, vol.7, 2019.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI